NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, reinforces its commitment to progressing research of racial disparities in breast cancer through two poster presentations.
Read MoreAgendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer.
Read MoreAgendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendia’s progress in developing practice-changing evidence to improve personalized cancer care Read More